MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from exercise of
warrants, net of offering...
$634,922
Net cash provided by
financing activities
$634,922
Net increase in cash
and cash...
-$416,045
Canceled cashflow
$634,922
Common stock issued for
research and development
$518,225
Stock-based compensation
$47,267
Amortization expense
$2,938
Unrealized loss on crypto
assets
-$2,690
Net cash used in
operating activities
-$955,493
Canceled cashflow
$571,120
Net cash provided by
investing activities
-$95,474
Net loss
-$1,110,438
Accounts payable and
accrued expenses
-$341,558
Prepaid expenses and
other current assets
$56,592
Deferred revenue
-$18,025
Purchases of crypto assets
$74,973
Purchases of short-term
investments
$20,501
Back
Back
Cash Flow
source: myfinsight.com
Silo Pharma, Inc. (SILO)
Silo Pharma, Inc. (SILO)